Recombinant erythropoietin in clinical practice

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Postgraduate medical journal

• Publication date

  2003-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/pmj.79.933.367PMID 12897214PMCID PMC1742767
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Practical Transfusion Medicine

  2009cited by this paper
• Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.

  2005cited by this paper
• Autologous transfusion

  2004cited by this paper
• The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron.

  2003cited by this paper
• Predictive factors for suicidal ideation in patients with unresectable lung carcinoma

  2002cited by this paper
• Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial

  2002cited by this paper
• Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy

  2002cited by this paper
• Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma

  2002cited by this paper
• Continuous Intravenous Sodium Ferric Gluconate Improves Efficacy in the Maintenance Phase of EPOrHu Administration in Hemodialysis Patients

  2002cited by this paper
• Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.

  2002cited by this paper
• The importance of anemia and its correction in the management of severe congestive heart failure

  2002cited by this paper
• Pure red-cell aplasia and recombinant erythropoietin.

  2002cited by this paper
• Pure red-cell aplasia and recombinant erythropoietin.

  2002cited by this paper
• Unexpected Renal Actions of Erythropoietin

  2002cited by this paper
• Antibodies against rHuEPO: native and recombinant.

  2002cited by this paper
• Abnormal renal phenotype in L1 knockout mice: a novel cause of CAKUT.

  2002cited by this paper
• CMV and blood transfusions

  2002cited by this paper
• Recombinant human erythropoietin administration in cardiac surgery.

  2001cited by this paper
• The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.

  2001cited by this paper
• Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency.

  2001cited by this paper
• Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial*

  2001cited by this paper
• Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. final results of a randomized phase III study

  2001cited by this paper
• Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models

  2001cited by this paper
• Subcutaneous Low-Dose Epoetin Beta for the Avoidance of Transfusion in Patients Scheduled for Elective Surgery Not Eligible for Autologous Blood Donation

  2001cited by this paper
• Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients.

  2001cited by this paper
• Beyond erythropoiesis: novel applications for recombinant human erythropoietin.

  2001cited by this paper
• Erythropoietin can obviate the need for repeated heart valve replacement in high-risk patients with severe mechanical hemolytic anemia: case reports and literature review.

  2001cited by this paper
• A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy

  2001cited by this paper
• Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer

  2001cited by this paper
• The impact of hemoglobin levels on treatment outcomes in patients with cancer.

  2001cited by this paper
• Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat.

  2001cited by this paper
• Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure.

  2001cited by this paper
• Plasma total homocysteine concentration in nephrotic patients with idiopathic membranous nephropathy.

  2001cited by this paper
• Red blood cell transfusion does not increase oxygen consumption in critically ill septic patients

  2001cited by this paper
• An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP).

  2001cited by this paper
• THE USE OF PRETRANSPLANT ERYTHROPOIETIN TO NORMALIZE HEMOGLOBIN LEVELS HAS NO DELETERIOUS EFFECTS ON RENAL TRANSPLANTATION OUTCOME1

  2001cited by this paper
• Red blood cell transfusions in very and extremely low birthweight infants under restrictive transfusion guidelines: is exogenous erythropoietin necessary?

  2001cited by this paper
• Clinical experience with epoetin alfa in the management of hemoglobin levels in orthopedic surgery and cancer. Implications for use in gynecologic surgery.

  2001cited by this paper
• Obesity as a risk factor in renal transplant patients.

  2001cited by this paper
• The effect of the transfusion of stored RBCs on intestinal microvascular oxygenation in the rat

  2001cited by this paper
• The importance of early treatment of the anaemia of chronic kidney disease.

  2001cited by this paper
• Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment.

  2001cited by this paper
• Cardiovascular Mortality in Haemodialysis Patients Treated with Epoetin Beta – A Retrospective Study

  2000cited by this paper
• Erythropoietin and the incidence of necrotizing enterocolitis in infants with very low birth weight.

  2000cited by this paper
• Recombinant erythropoietin therapy as an alternative to blood transfusions in infants with hereditary spherocytosis.

  2000cited by this paper
• Prospective investigation of transfusion transmitted infection in recipients of over 20 000 units of blood

  2000cited by this paper
• Blood boosting and sport.

  2000cited by this paper
• Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients

  2000cited by this paper
• Red Blood Cell Function and Blood Storage

  2000cited by this paper
• Consensus statement: anemia in HIV infection--current trends, treatment options, and practice strategies. Anemia in HIV Working Group.

  2000cited by this paper
• Anemia in inflammatory bowel disease - the role of recombinant human erythropoietin.

  2000cited by this paper
• Prospective investigation of transfusion transmitted infection in recipients of over 20 000 units of blood. TTI Study Group.

  2000cited by this paper
• Use of Erythropoietin and Its Effects on Blood Lactate and 2,3-Diphosphoglycerate in Premature Neonates

  2000cited by this paper
• Allogeneic blood transfusion as a risk factor for the subsequent development of non-Hodgkin's lymphoma.

  2000cited by this paper
• Factors Associated with Successful Epoetin Alfa Therapy in Premature Infants

  2000cited by this paper
• Pure red cell aplasia as presentation of systemic lupus erythematosus: antibodies to erythropoietin.

  1999cited by this paper
• Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures

  1999cited by this paper
• Erythropoietin and renal transplantation.

  1999cited by this paper
• Primary and revision total hip replacement in patients who are Jehovah's Witnesses.

  1999cited by this paper
• The erythropoietin receptor.

  1999cited by this paper
• Clinical use of rHuEPO in bone marrow transplantation

  1999cited by this paper
• Comparison of Intraperitoneal and Subcutaneous Epoetin Alfa in Peritoneal Dialysis Patients a

  1999cited by this paper
• [Prevention of neonatal anemia with recombinant human erythropoietin: a cost-benefit analysis].

  1999cited by this paper
• DIE PROPHYLAXE DER FRUHGEBORENENANAMIE MIT REKOMBINANTEM HUMANEN ERYTHROPOIETIN: EINE KOSTEN-NUTZEN-ANALYSE

  1999cited by this paper
• Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

  1998cited by this paper
• Anemia and survival in HIV infection.

  1998cited by this paper
• The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy

  1998cited by this paper
• Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy

  1998cited by this paper
• The Role of Recombinant Human Erythropoietin in the Treatment of Thalassemia

  1998cited by this paper
• Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours.

  1998cited by this paper
• Effect of recombinant human erythropoietin on lymphocyte phenotyping and phagocyte activity in hemodialysis patients.

  1997cited by this paper
• Randomised controlled double blind study of role of recombinant erythropoietin in the prevention of chronic lung disease

  1997cited by this paper
• Anaemia of prematurity. Epidemiology, management and costs.

  1997cited by this paper
• Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

  1997cited by this paper
• Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia.

  1997cited by this paper
• Open-Heart Surgery in Jehovah's Witness Patients

  1996cited by this paper
• Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2.

  1996cited by this paper
• Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma.

  1996cited by this paper
• Recombinant erythropoietin for prevention of anemia in preterm infants

  1995cited by this paper
• Evidence-based recommendations for the clinical use of recombinant human erythropoietin.

  1995cited by this paper
• Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response.

  1995cited by this paper
• The production of recombinant human erythropoietin.

  1995cited by this paper
• Efficacy of erythropoietin in the myelodysplastic syndromes: a meta‐analysis of 205 patients from 17 studies

  1995cited by this paper
• Management of blood loss in Jehovah's Witnesses

  1995cited by this paper
• Erythropoietin: the promise and the facts.

  1994cited by this paper
• Erythropoietin and neonatal anemia.

  1994cited by this paper
• Recombinant human erythropoietin and the anemia of cancer.

  1994cited by this paper
• Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo.

  1994cited by this paper
• Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.

  1993cited by this paper
• Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy.

  1993cited by this paper
• Recombinant Human Erythropoietin Treatment: Investigational New Drug Protocol for the Anemia of the Acquired Immunodeficiency Syndrome: Overall Results

  1993cited by this paper
• Recombinant Human Erythropoietin in the Treatment of Anemia Associated with Human Immunodeficiency Virus (HIV) Infection and Zidovudine Therapy: Overview of Four Clinical Trials

  1992cited by this paper
• Blood transfusion in marrow graft recipients

  1992cited by this paper
• Erythropoietin: structure, control of production, and function.

  1992cited by this paper
• Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials.

  1992cited by this paper
• Autologous transfusion.

  1991cited by this paper
• Decreased erythropoietin response in patients with the anemia of cancer.

  1990cited by this paper
• Blood Transfusion Policy

  1989cited by this paper
• Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.

  1989cited by this paper
• Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease.

  1989cited by this paper

• Quantum Dot Erythropoietin Bioconjugates Enhance EPO-Receptor Clustering on Transfected Human Embryonic Kidney Cells.

  2025cites this paper
• Repurposing of erythropoietin as a neuroprotective agent against methotrexate-induced neurotoxicity in rats

  2024cites this paper
• Cell line development for human erythropoietin with two additional N-links in CHO-DG44 cells

  2023cites this paper
• Achieving routine application of dried blood spots for erythropoietin receptor agonist analysis in doping control: low-volume single-spot detection at minimum required performance level.

  2023cites this paper
• Association of Angiotensin Converting Enzyme gene polymorphism in anemic patients with regular haemodialysis in Sohag University Hospital

  2022cites this paper
• Optimizing detection of erythropoietin receptor agonists from dried blood spots for anti‐doping application

  2022cites this paper
• Emerging principles of cytokine pharmacology and therapeutics

  2022cites this paper
• Erythropoietin as a Neuroprotective Drug for Newborn Infants: Ten Years after the First Use

  2022cites this paper
• Benign Hematologic Disorders in Children: A Clinical Guide

  2021cites this paper
• Modified recombinant human erythropoietin with potentially reduced immunogenicity

  2021cites this paper
• Whether Erythropoietin can be a Neuroprotective Agent against Premature Brain Injury: Cellular Mechanisms and Clinical Efficacy

  2021cites this paper
• Haematological Indicators of Response to Erythropoietin Therapy in Chronic Renal Failure Patients on Haemodialysis: Impact of Angiotensin-Converting Enzyme rs4343 Gene Polymorphism

  2021cites this paper
• Immunoaffinity Capillary Electrophoresis in the Era of Proteoforms, Liquid Biopsy and Preventive Medicine: A Potential Impact in the Diagnosis and Monitoring of Disease Progression

  2021cites this paper
• Transcriptomic Markers of Recombinant Human Erythropoietin Micro-Dosing in Thoroughbred Horses

  2021cites this paper
• Review of Oncology and Transplant Literature for the Management of Hepatic and Pancreatic Resections in Jehovah's Witnesses.

  2021cites this paper
• Treatment of Neonatal Hypoxic-Ischemic Encephalopathy with Erythropoietin Alone, and Erythropoietin Combined with Hypothermia: History, Current Status, and Future Research

  2020cites this paper
• Interleukin 3 as an Erythropoietic Marker in Human Immunodeficiency Virus and Hepatitis B Positive Patients in South East Nigeria

  2020cites this paper
• Mesenchymal stem cells as carrier of the therapeutic agent in the gene therapy of blood disorders

  2020cites this paper
• Transfusion Medicine for Pediatrics

  2020cites this paper
• The Endoplasmic Reticulum Cargo Receptor SURF4 Facilitates Efficient Erythropoietin Secretion

  2020cites this paper
• DEVELOPMENT OF PROTEIN DRUGS

  2020cites this paper
• Recent Advances in Capillary Electrochromatography of Proteins and Carbohydrates in the Biopharmaceutical and Biomedical Field

  2020cites this paper
• Erythropoietin regulation of red blood cell production: from bench to bedside and back

  2020cites this paper
• In vivo validation of a reversible small molecule-based switch for synthetic self-amplifying mRNA regulation.

  2020cites this paper
• The ER cargo receptor SURF4 facilitates efficient erythropoietin secretion

  2019cites this paper
• Erythropoietin as a Neuroprotective Molecule: An Overview of Its Therapeutic Potential in Neurodegenerative Diseases

  2019cites this paper
• Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach

  2019cites this paper
• The Promises and Challenges of Erythropoietin for Treatment of Alzheimer’s Disease

  2019cites this paper
• Medicina del deporte

  2019cites this paper
• RECOMBINANT HUMAN ERYTHROPOIETIN IN THE MANAGEMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE (NON-DIALYSIS) PATIENTS

  2018cites this paper
• Physicochemical screening for chemical stabilizer of erythropoietin to prevent its aggregation

  2018cites this paper
• A truncating mutation in EPOR leads to hypo-responsiveness to erythropoietin with normal haemoglobin

  2018cites this paper
• Validation of whole-blood transcriptome signature during microdose recombinant human erythropoietin (rHuEpo) administration

  2017cites this paper
• Harms of off-label erythropoiesis-stimulating agents for critically ill people.

  2017cites this paper
• Erythropoietin and thrombopoietin mimetics: Natural alternatives to erythrocyte and platelet disorders.

  2016cites this paper
• Exploring Erythropoietin and G-CSF Combination Therapy in Chronic Stroke Patients

  2016cites this paper
• A protocol avoiding allogeneic transfusion in joint arthroplasties

  2016cites this paper
• Variabilidad de los niveles de hemoglobina en pacientes tratados con agentes estimulantes de la eritropoyesis en pre-diálisis

  2016cites this paper
• Purification of human anti-erythropoietin polyclonal antibodies by precipitation and chromatography as an optimized method with potential application in vaccine studies

  2016cites this paper
• Variabilitat dels nivells d’hemoglobina en pacients tractats amb agents estimulants de l’eritropoesi en pre-diàlisi

  2016cites this paper
• Pharmacokinetic and Pharmacodynamic Comparison of Two Recombinant Human Erythropoietin Formulations, PDA10 and Eprex, in Healthy Korean Male Volunteers: A Randomized, Double-Blinded, Single-Dose, Two-Period Crossover Study

  2015cites this paper
• Effects of Human Erythropoietin on Functional Outcome of Patients with Traumatic Cervical Cord Injury; A Pilot Randomized Clinical Trial.

  2015cites this paper
• Capillary zone electrophoresis method for the direct determination of amino acids in recombinant human erythropoietin preparations used for the treatment of anemia

  2015cites this paper
• Resistance of dialyzed patients to erythropoietin

  2015cites this paper
• Erythropoietin Therapy for Heart Failure

  2014cites this paper
• Blood transfusion in surgery

  2014cites this paper
• Influencia de administración de eritropoyetina humana recombinante en el rendimiento físico: un estudio de revisión

  2014cites this paper
• Effectiveness and safety of erythropoiesis-stimulating agent use in the perioperative period

  2014cites this paper
• Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats

  2014cites this paper
• Erythropoietin and Diabetic Retinopathy

  2013cites this paper
• Screening and identification of genetic loci involved in producing more/denser inclusion bodies in Escherichia coli

  2013cites this paper
• Erythropoietin prevents hypoxia-induced GATA-4 ubiquitination via phosphorylation of serine 105 of GATA-4.

  2013cites this paper
• Human Ubiquitin C Promoter Based Expression of Erythropoietin in CHO K1 Cell Lines: A Simple Transfectants Screening Approach

  2013cites this paper
• Production of human erythropoietin in transgenic canola employing the technology of oleosin fusion

  2013cites this paper
• Desenvolvimento de ensaio imunoquímico para detecção de doping com eritropoetina

  2013cites this paper
• Aberrant phenotypes of transgenic mice expressing dimeric human erythropoietin

  2012cites this paper
• "Doping no esporte: uso de eritropoietina, propriedades, efeitos e detecção"

  2012cites this paper
• Use FACS sorting in metabolic engineering of Escherichia coli for increased peptide production.

  2012cites this paper
• Erythropoietin use and abuse

  2012cites this paper
• Development of Radiolabeled Recombinant Erythropoietin for Receptor Studies

  2012cites this paper
• Evaluation of the effect of one large dose of erythropoietin against cardiac and cerebral ischemic injury occurring during cardiac surgery with cardiopulmonary bypass: a randomized double‐blind placebo‐controlled pilot study

  2012cites this paper
• Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study

  2012cites this paper
• Protection tissulaire dans l'arrêt circulatoire : du massage cardiaque à la protection pharmacologique. Approche clinique et expérimentale

  2011cites this paper
• Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis

  2011cites this paper
• Molecular Cloning and Transgenic Expression of a Synthetic Human Erythropoietin Gene in Tobacco

  2011cites this paper
• Saving Mothers’ Lives. Reviewing maternal deaths to make motherhood safer: 2006–2008

  2011cites this paper
• Therapie mit Immunsuppressiva und Immunmodulatoren

  2010cites this paper
• Capítulo 24 – Transfusión de hematíes y métodos de ahorro de sangre. Eritropoyetina

  2010cites this paper
• Efficacy and Safety of ior® EPOCIM for Chemotherapy- or Radiotherapy-Induced Anemia in Pediatric Cancer Patients

  2010cites this paper
• Effectiveness of treating the renal anemia in chronic hemodialyzed patients by epoietin alpha and beta.

  2010cites this paper
• Biotechnology-Derived Medicines: What are They? A Pharmacological and a Historical Perspective

  2010cites this paper
• Efficacy and safety of iorEPOCIM for chemotherapy- or radiotherapy-induced anemia in pediatric cancer patients.

  2010cites this paper
• Molecular Basis of Cardioprotection by Erythropoietin

  2009cites this paper
• HUMAN RECOMBINANT ERYTHROPOIETIN IN THE TREATMENT OF ANEMIA OF PATIENTS WITH CHRONIC RENAL FAILURE

  2009cites this paper
• Erythropoietin activates nitric oxide synthase in murine erythrocytes.

  2009cites this paper
• [Erythropoietin: indications and measurement].

  2009influential citation
• Molecular basis of cardioprotection by erythropoietin.

  2009cites this paper
• PDpoietin in comparison with Eprex in treatment of anemic patients on hemodialysis.

  2009cites this paper
• Erythropoietin attenuates lung injury in lipopolysaccharide treated rats.

  2009cites this paper
• Centrifugal recovery of embryonic stem cells for regenerativemedicine bioprocessing

  2009cites this paper
• Gene therapy by electroporation for the treatment of chronic renal failure in companion animals

  2009cites this paper
• Effect of erythropoietin on human tumor growth in xenograft models.

  2009cites this paper
• Circulating Chemokine Levels in Febrile Infants With Serious Bacterial Infections

  2009cites this paper
• Expressão Transgênica da Eritropoietina Humana em Plantas

  2008cites this paper
• Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease.

  2008cites this paper
• Eritropoyetina recombinante humana en pacientes con enfermedad renal crónica en etapa de prediálisis

  2008cites this paper
• The assessment of native erythropoietin and antibodies to recombinant erythropoietin in haemodialysis patients

  2008cites this paper
• Hemoglobin and Hematocrit Rise in End-Stage Renal Disease (ESRD) with PDpoetin: Results of a Phase Ш, Multicenter Clinical Trial

  2008cites this paper
• A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.

  2007cites this paper
• Erythropoietin Physiology, Clinical, and Laboratory Aspect

  2007cites this paper
• Erythropoietin pharmacology

  2007cites this paper
• Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.

  2007cites this paper
• Isoelectric profiles of human erythropoietin are different in serum and urine.

  2007cites this paper
• Oxygen breathing may be a cheaper and safer alternative to exogenous erythropoietin (EPO).

  2007cites this paper
• Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia.

  2007cites this paper
• Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins

  2007cites this paper
• Ciruga cardiaca en testigos de Jehov. Experiencia en Santander

  2006cites this paper
• Recombinant Human Erythropoietin in Severe Anaemia: Issues of Dosing and Duration

  2006cites this paper
• Erythropoietin - measurement and clinical applications

  2006cites this paper
• Adjusting i.v. iron and EPO doses in patients on hemodialysis prior to continuing surgery: can we protect our patients education from iron-deficiency anemia?

  2006cites this paper